Scholar Rock

Scholar Rock is a clinical-stage biopharmaceutical company that discovers and develops selective inhibitors of protein growth factor activation to treat severe neuromuscular and autoimmune disorders. The company’s lead therapeutic candidate, apitegromab, selectively blocks the activation of latent myostatin to preserve and restore motor muscle function in spinal muscular atrophy patients. By targeting extracellular growth factor precursors rather than mature signaling proteins, Scholar Rock unlocks new frontiers in structural biology.